ArticleAnnals of medicine2025
Combined serum amyloid A and heparin-binding protein levels on admission reliably predict the severity and outcomes of COVID-19 infection in elderly patients: a retrospective study from Hangzhou, China.
Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesIndicators that predict the severity and outcomes of COVID-19 are essential to guide medical decision-making. This retrospective study explored whether the combined levels of serum amyloid A (SAA) and heparin-binding protein (HBP) in elderly COVID-19 patients are useful in this context. PATIENTS: This retrospective study included COVID-19 patients aged ≥ 60 years admitted to a designated hospital in Hangzhou, China between December 2022 and March 2023. The clinical, epidemiological, radiological, and laboratory parameters of the patients were analyzed.
resultsCompared with COVID-19 survivors, the levels of HBP, procalcitonin, SAA, C-reactive protein, D-dimer, and interleukin-6, as well as the white blood cell and neutrophil counts, were significantly elevated in non-survivors, whereas the total protein and lymphocyte count were lower. The admission SAA and HBP levels were significantly elevated in COVID-19 patients compared with reference values and increased with disease severity. Receiver operating characteristic curves were used to evaluate the diagnostic utility of SAA plus HBP levels for predicting COVID-19-associated mortality. An SAA level cut-off of 348.73 mg/L combined with HBP level cut-off of 42.75 ng/mL showed a sensitivity, specificity, and area under the curve of 96.7%, 85.7%, and 0.96, respectively. An admission SAA level ≥ 348.73 mg/L and HBP level ≥ 42.75 ng/mL increased the risk of unfavorable outcomes in elderly COVID-19 patients.
conclusionCombined admission levels of SAA and HBP reliably predicted COVID-19 severity and prognosis in patients aged ≥ 60 years. Elderly patients with elevated SAA and HBP levels at admission should receive aggressive and timely treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.